ARTICLE | Clinical News
AI-401: Began Phase I trial
January 17, 1994 8:00 AM UTC
AutoImmune Inc. (AIMM) Lexington, Mass. Product: AI-401, recombinant human insulin Indication: Oral tolerance therapy for Type I diabetes Status: Began Phase I trial ...